WO2018124704A1 - 알룰로스를 포함하는, 식물성 유지의 생체 외 배출 촉진용 조성물 - Google Patents
알룰로스를 포함하는, 식물성 유지의 생체 외 배출 촉진용 조성물 Download PDFInfo
- Publication number
- WO2018124704A1 WO2018124704A1 PCT/KR2017/015496 KR2017015496W WO2018124704A1 WO 2018124704 A1 WO2018124704 A1 WO 2018124704A1 KR 2017015496 W KR2017015496 W KR 2017015496W WO 2018124704 A1 WO2018124704 A1 WO 2018124704A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- allulose
- composition
- food
- vegetable
- Prior art date
Links
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000029142 excretion Effects 0.000 title claims abstract description 18
- 150000002632 lipids Chemical class 0.000 title claims abstract description 17
- 230000001737 promoting effect Effects 0.000 title claims abstract description 8
- 235000013311 vegetables Nutrition 0.000 title claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 31
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 36
- 239000008158 vegetable oil Substances 0.000 claims description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 31
- 239000003921 oil Substances 0.000 claims description 21
- 239000003925 fat Substances 0.000 claims description 19
- 235000019871 vegetable fat Nutrition 0.000 claims description 19
- 235000019198 oils Nutrition 0.000 claims description 18
- 210000003608 fece Anatomy 0.000 claims description 17
- 239000003549 soybean oil Substances 0.000 claims description 16
- 235000012424 soybean oil Nutrition 0.000 claims description 16
- 235000019482 Palm oil Nutrition 0.000 claims description 15
- 235000012000 cholesterol Nutrition 0.000 claims description 15
- 239000003264 margarine Substances 0.000 claims description 15
- 235000013310 margarine Nutrition 0.000 claims description 15
- 239000002540 palm oil Substances 0.000 claims description 15
- 235000021588 free fatty acids Nutrition 0.000 claims description 13
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 10
- 235000013376 functional food Nutrition 0.000 claims description 9
- 150000003626 triacylglycerols Chemical class 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- 235000005687 corn oil Nutrition 0.000 claims description 5
- 239000002285 corn oil Substances 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 4
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims 2
- 235000008390 olive oil Nutrition 0.000 claims 2
- 235000009200 high fat diet Nutrition 0.000 description 35
- 235000005911 diet Nutrition 0.000 description 19
- 230000037213 diet Effects 0.000 description 19
- 239000013642 negative control Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- -1 olive oil Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000057621 Glycerol kinases Human genes 0.000 description 2
- 108700016170 Glycerol kinases Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102000043296 Lipoprotein lipases Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003044 randomized block design Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 1
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 102100037458 Dephospho-CoA kinase Human genes 0.000 description 1
- 101000952691 Homo sapiens Dephospho-CoA kinase Proteins 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- RSYUFYQTACJFML-DZGCQCFKSA-N afzelechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-DZGCQCFKSA-N 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- 229910000009 copper(II) carbonate Inorganic materials 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000011646 cupric carbonate Substances 0.000 description 1
- 235000019854 cupric carbonate Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- AWUCVROLDVIAJX-VKHMYHEASA-N sn-glycerol 1-phosphate Chemical compound OC[C@H](O)COP(O)(O)=O AWUCVROLDVIAJX-VKHMYHEASA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/04—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing non-milk fats but no non-milk proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Definitions
- the present application relates to a composition for promoting ex vivo excretion of vegetable oils and fats, including allulose.
- D-psicose is a C-3 epimer of D-fructose, a natural sugar present in trace amounts in a commercial mixture of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose. to be. It was recognized by the United States Department of Agriculture (USDA) as a General Recognized As Safe (GRAS). Since allulose is not metabolized in the human body, there is almost no calories, and has a sweetness of 70% compared to sugar, so it is a sweetener that can replace sugar, and its development is being actively performed. Recently, studies have reported that allulose affects lipid metabolism (Yasuo nagata et al., J. Agric, Food Chem. 2015, 63, 3168-3176). None reported.
- the present application provides a composition for promoting ex vivo release of vegetable fats (vegetable lipids) comprising allulose.
- Allulose used in the present application may be directly extracted from natural products, may be prepared by chemical synthesis, or biological methods, but is not limited thereto.
- the allulose included in the creamer of the present application may be liquid or crystalline allulose.
- the allulose may be crystalline allulose, and more specifically, the crystalline allulose may have an allulose purity of 90% to 99.5%.
- Vegetable oil of the present application is soybean oil (soy bean oil), olive oil (olive oil), palm oil (palm oil), corn oil (corn oil), palm olein oil, palm stearin oil (palm stearin oil), It may be at least one vegetable oil selected from the group consisting of coconut oil, canola oil and sunflower oil and their cured oils.
- the emission in the present application may be an emission of triglycerides, cholesterol, free fatty acids or combinations thereof.
- the discharge of the present application may be a discharge to feces.
- composition for promoting in vitro release of vegetable oil or fat of the present application may be a pharmaceutical composition, a functional food composition or a food composition.
- composition of the present application may be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and specifically orally.
- composition of the present application may further include one or more pharmaceutically acceptable carriers in addition to allulose for administration.
- pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, as antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added.
- Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it can be formulated according to each disease or component by any suitable method in the art or using methods disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.
- the dosage of the pharmaceutical composition of the present application varies in the range depending on the weight, age, sex, health condition, diet, time of administration, administration method, excretion rate and severity of disease of the patient.
- the allulose of the present application may be about 0.0001 to 600 mg / kg, specifically about 0.001 to 500 mg / kg, and may be administered once to several times a day.
- composition of the present application can be used alone or in combination with methods using surgery, hormonal therapy, drug therapy and biological response modifiers.
- the composition of the present application can be used as a food or functional food composition.
- the allulose may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method.
- the mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
- the food or functional food composition may be included without limitation so long as the food or functional food composition containing a vegetable oil or fat. Examples of food or functional food compositions of the present application include meat, sausage, bread, cake.
- the food or functional food composition of the present application includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, Glycerin, alcohol, carbonation agent used for carbonated drinks, and the like. These components can be used independently or in combination.
- the ratio of such additives may be selected in the range of 0.01 to 0.20 parts by weight per 100 parts by weight of the food or functional food composition of the present application.
- the present application provides a food comprising the composition and vegetable oils and fats of the present application.
- the allulose may be included in 20 to 150 parts by weight based on 100 parts by weight of the vegetable oil.
- the food of the present application may be margarine or creamer. More specifically, the margarine of the present application may further include one or more components selected from the group consisting of water, sodium chloride, milk, lecithin, organic acids and emulsifiers.
- the creamer of the present application may further include casein, maltose and phosphate.
- the creamer of the present application may be in a powder state, and specifically, may have a water content of 0.5% to 5%.
- the creamer of the present application may be a coffee creamer or a tea creamer.
- allulose may be included in an amount of 20 to 150 parts by weight based on 100 parts by weight of vegetable oil or fat.
- the content of allulose is 20 to 100 parts by weight, 20 to 50 parts by weight, 20 to 40 parts by weight, 30 to 150 parts by weight, 30 parts by weight based on 100 parts by weight of the vegetable oil and fat.
- the food of the present application may not include sugar.
- the composition, the vegetable oil and the description of the food is as described in the above-described embodiment.
- the present application comprises the step of administering the vegetable oil to the subject, and administering allulose to the subject before, after, or simultaneously with the step of administering the vegetable oil to the subject,
- the subject may be a human or animal.
- the allulose may be administered in an amount of 20 parts by weight to 150 parts by weight based on 100 parts by weight of the vegetable fat ingested by the subject, and specifically, the allulose may be used in 100 parts by weight of the vegetable fat or oil.
- 20 to 100 parts by weight, 20 to 50 parts by weight, 20 to 40 parts by weight, 30 to 150 parts by weight, 30 to 100 parts by weight, 30 to 50 parts by weight or 30 to parts by weight 40 parts by weight may be administered.
- the administration can be oral administration.
- the present application relates to the use of a composition comprising allulose for promoting the release of vegetable oils contained in food.
- the present application has shown that allulose is provided with vegetable fats and oils to significantly increase lipid excretion into the feces, thereby reducing consumer concerns about fat or oil intake due to the ingestion of vegetable fats or foods containing the same. It has an effect.
- FIGS. 1A-1D are a view of body weight change for 8 weeks in C57BL / 6J mice fed with vegetable fat containing high fat diet (HFD) with allulose.
- HFD vegetable fat containing high fat diet
- the abbreviations of the controls are as follows (OL: olive oil, MG: margarine, PO: palm oil, SO: soybean oil).
- the abbreviation of the experimental group is as follows (OLA: olive oil + 5% allulose provided, w / w, MGA: margarine + 5% allulose provided, w / w, POA: palm oil + 5% Allulose provided, w / w, SOA: soybean oil + 5% allulose provided, w / w)).
- Figure 1e is a view of the weight change for 8 weeks in C57BL / 6J mice fed creamer-containing high-fat diet (HFD) with allulose.
- the PR of the control group provided the high fat diet (HFD) with the primer
- the PRA provided the high fat diet (HFD) + creamer + 5% allulose (w / w).
- FIG. 2A is a diagram illustrating the change in fecal lipid excretion after 8 weeks in C57BL / 6J mice fed with vegetable fat containing high fat diet (HFD) together with allulose.
- HFD vegetable fat containing high fat diet
- the data are mean ⁇ SE.
- the effective values between the allulose free group and the 5% allulose group are as follows; * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
- HFD high fat diet
- each abbreviation is as follows: OLA, HFD + olive oil + 5% allulose (w / w); OL, HFD + olive oil; MGA, HFD + margarine + 5% allulose (w / w); MG, HFD + margarine; POA, HFD + palm oil + 5% allulose (w / w); PO, HFD + palm oil; SOA, HFD + soybean oil + 5% allulose (w / w); OL, HFD + soybean oil.
- Figure 2b is a view of the change in fecal lipid excretion after 8 weeks in C57BL / 6J mice fed creamer-containing high-fat diet (HFD) with allulose.
- HFD creamer-containing high-fat diet
- the data are mean ⁇ SE.
- the effective values between the allulose free group and the 5% allulose group are as follows; * p ⁇ 0.05, ** p ⁇ 0.01, *** p ⁇ 0.001.
- PRA is "HFD + Creamer + 5% Allulose (w / w)" and PR is "Creamer + HFD”.
- Palm oil olive oil, soybean oil, margarine
- mice 20 C57BL / 6J mice (male, 4 week old) were purchased from The Jackson Laboratory (USA) and used. After 4 weeks of acclimatization with a lab-chow diet (Purina co. USA), a negative control group (10/1 oil and fat) that do not consume allulose using a randomized block design is used. It consisted of two groups of experimental groups [10 mice / 1 oil] ingesting a loin to provide a diet for 8 weeks.
- Negative control diet applies high-fat diet to AIN-76 diet but maintains vegetable oil (palm oil (Wilmar, Malaysia), olive oil (CJ CheilJedang, Korea), soybean oil (CJ Cheil Jedang, Korea), margarine (Margarine, Ottogi 'corn magarin) ', Raw material: vegetable oil (palm olein oil, palm stearin oil, palm oil, corn oil) 80% by weight] was used as a negative control diet 5% by weight of sugar in the negative control diet.
- Tin 1 Mineral mix: AIN-76 mineral mixture (gram / kg): calcium phosphate, 500; sodium chloride, 74; potassium citrate, 2220; potassium sulfate, 52; magnesium oxide, 24; managanous carbonate, 3.5; ferric citrate, 6; zinc carbonate, 1.6; cupric carbonate, 0.3; potassium iodate, 0.01; sodium celenite, 0.01; chromium potassium sulfate, 0.55; sucrose 118.03
- Vitamin mix AIN-76 vitamin mixture (gram / kg): thiathia HCL, 0.6; riboflavin, 0.6; pyridoxine HCL, 0.7; nicotinic acid, 0.003; D-calcium pantothenate, 0.0016; folate, 0.2; D-biotin, 0.02; cyanocobalamin (vitamin B12), 0.001; retinyl palmitate premix, 0.8; DL-alpha tocopheryl acetate, premix, 20; cholecalciferol (vitamin D3), 0.0025; menaquinone (vitamin K), 0.05; antioxidant, 0.01; sucrose, finely powdered, 972.8
- Negative control diet was applied to AIN-76 diet with high fat diet but with vegetable oil creamer [East-West food 'prima', Korea, raw material: 30-38% by weight of vegetable hardened oil (palm hardened oil, palm hardened oil), starch syrup ( Maltose), sodium caseinate, potassium diphosphate, tricalcium phosphate] were used.
- the experimental group diet was used by replacing 5% by weight of sugar in the components of the negative control diet with allulose (crystalline allulose, more than 98% by weight of allulose on dry solids, CJ CheilJedang) (Table 2). All animal experiments were carried out with the approval of the Animal Experimental Ethics Committee of Kyungpook National University, Korea (approved number: KNU-2013-18).
- mice By feeding the same level of iso-energetic diet by conducting pair feeding based on the experimental group, calorie reduction effect by allulose was excluded, and the diet was refrigerated at 4 ° C during the breeding period. It was. The mice were housed in individual cages under constant temperature (25 ⁇ 2 ° C.), constant humidity (50 ⁇ 5%) and dark-light cycles at 12 hour intervals.
- Dietary intake was measured at a certain time every day, and weight at a certain time each week.
- Feces were collected for 84 hours (3.5 days) after the end of breeding, dried and stored frozen.
- Folch et al. (1957) were modified and supplemented to measure fecal triglycerides, cholesterol and free fatty acids. Specifically, 0.5 g of the dried feces were ground in a mortar and 5 mL chloroform: methanol (2: 1, v / v) solution was added to extract lipids at 4 ° C. for 24 hours. The extract was centrifuged at 3000 ⁇ g (4 ° C.) for 10 minutes, 3 ml of the supernatant was dried over nitrogen at 37 ° C. and dissolved in 1 mL of the same extractant.
- triglyceride 200 ⁇ L of triglyceride, cholesterol, and free fatty acid were respectively taken, dried with nitrogen gas, and neutral lipid, total cholesterol, was dissolved in 500 ⁇ L of ethanol.
- free fatty acid measurement was dissolved in 2.25ml NaOH and then adjusted to the pH 2-3 range by adding 1M HCl solution.
- 3 mM cholic acid (sodium salt) as an emulsifier and 0.5% Triton X-100 were used to remove turbidity during color development.
- FC free cholesterol
- CE ester type cholesterol
- the resulting product and the substrate, H 2 O 2 were reacted with peroxidase, phenol, and 4-amino-antipyrine to obtain a red colored substance, and then absorbance was measured at 500 nm. The measurements were quantified by comparison with the cholesterol standard curve.
- triglycerides 10 ⁇ L of a solution dissolved in 500 ⁇ L ethanol and 690 ⁇ L of an emulsifier were mixed, and 800 ⁇ L of a measuring solution (Asan Pharmaceutical kit) applying the enzyme method of McGowan et al. (1983) was mixed.
- Neutral lipids were broken down into glycerol and fatty acids by lipoprotein lipase (LPL).
- LPL lipoprotein lipase
- Glycerol in the digest formed L- ⁇ -glycerol phosphate under the action of ATP and glycerol kinase (GK), which reacted with O 2 and glycerophosphooxidase (GPO) to generate H 2 O 2 .
- GK glycerol kinase
- GPO glycerophosphooxidase
- Free fatty acid concentration was measured using a non-esterificed fatty acid solution (NEFA kit, Wako, Japan) according to the color development method using the enzyme method.
- acyl coenzyme A synthase was applied to plasma free fatty acid to generate acyl-CoA, AMP and pyrophosphoric acid.
- Acyl coenzyme A oxidase was then added thereto to produce 2,3-trans-enoryl-CoA and hydrogen peroxide. It was treated with peroxidase, 4-aminoantipyrine, and N-ethyl-N- (2-hydroxy-3-sulfoorofil) -m -toruidine to develop a red color, and then measured for absorbance at 546 nm. Quantification was compared with a standard curve.
- Palm oil olive oil, soybean oil, and margarine
- the weight of the negative control group and the experimental group was similar at the time of diet 0 weeks (Table 3), but after 8 weeks of diet was confirmed that the weight increase inhibitory effect of the experimental group compared to the negative control (Table 4 and Figures 1a to 1d).
- the weight increase inhibitory effect of the experimental group compared to the negative control (Table 4 and Figures 1a to 1d).
- the POA group from the diet 6 weeks it was confirmed that the significant weight increase inhibitory effect for the negative control group (Fig. 1a to 1c).
- the SOA group showed a weight increase inhibitory effect from the first week of the diet, it was confirmed that the weight increase inhibitory effect is more significant than other vegetable oils and fats (FIG.
- ** t-test is a comparison between allulose-free PR and PRA containing 5% by weight allulose in each group.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
Abstract
Description
구분 | 음성대조군(PR) | 실험군(PRA) |
Casein | 20 | 20 |
DL-Methionine | 0.3 | 0.3 |
Corn starch | 11.1 | 11.1 |
Sucrose | 37 | 32 |
Cellulose | 5 | 5 |
Creamer(Prima) | 14.6 | 14.6 |
Lard | 5.4 | 5.4 |
Mineral mix1) | 4.2 | 4.2 |
Vitamin mix2) | 1.2 | 1.2 |
Choline bitartrate | 0.2 | 0.2 |
Cholesterol | 1 | 1 |
tert-Butylhydroquinone | 0.004 | 0.004 |
Allulose | - | 5 |
Total (%) | 100 | 100 |
kcal/g diet | 4.047 | 4.847 |
Claims (11)
- 알룰로스를 포함하는, 식물성 유지(vegetable lipids)의 생체 외 배출 촉진용 조성물.
- 제1항에 있어서, 상기 식물성 유지는 대두유(soy bean oil), 올리브유(olive oil), 팜유(palm oil), 옥수수유(corn oil), 팜올레인유(palm olein oil), 팜스테아린유(palm stearin oil), 야자유(coconut oil), 카놀라유(canola oil) 및 해바라기유(sunflower oil) 및 이들의 경화유로 이루어진 군으로부터 선택되는 1종 이상의 식물성 유지인, 조성물.
- 제1항에 있어서, 상기 배출은 트리글리세리드, 콜레스테롤, 유리지방산 또는 이의 조합의 배출인, 조성물.
- 제1항에 있어서, 상기 배출은 분변으로의 배출인, 조성물.
- 제1항에 있어서, 상기 조성물은 약제학적 조성물, 기능성 식품용 조성물 또는 식품 조성물인, 조성물.
- 제1항의 조성물 및 식물성 유지를 포함하는 식품.
- 제6항에 있어서, 상기 알룰로스는 상기 식물성 유지 100 중량부에 대하여 건조 고형분 기준 20 중량부 내지 150 중량부로 포함되는, 식품.
- 제6항에 있어서, 상기 식품은 마아가린인 식품.
- 제8항에 있어서, 상기 식품은 물, 염화나트륨, 우유, 레시틴, 유기산 및 유화제로 이루어진 군으로부터 선택되는 1 이상의 성분을 추가로 포함하는, 식품.
- 식물성 유지를 대상체(subject)에 투여하는 단계, 및 상기 식물성 유지를 대상체에 투여하는 단계 이전, 이후 또는 동시에 알룰로스를 상기 대상체에 투여하는 단계를 포함하는, 상기 대상체에 투여된 식물성 유지의 생체 외로의 배출을 촉진하는 방법.
- 알룰로스를 포함하는 조성물의, 식품에 포함된 식물성 유지의 생체 외로의 배출 촉진을 위한 용도.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2019005996A MX2019005996A (es) | 2016-12-26 | 2017-12-26 | Composicion que contiene alulosa para promover la excrecion de lipidos vegetales del cuerpo. |
EP17887817.9A EP3560340A4 (en) | 2016-12-26 | 2017-12-26 | COMPOSITION FOR PROMOTING VEGETABLE LIPID EXCRETION AND COMPRISING ALLULOSIS |
BR112019008683-8A BR112019008683B1 (pt) | 2016-12-26 | 2017-12-26 | Margarina compreendendo alulose |
US16/468,345 US11191285B2 (en) | 2016-12-26 | 2017-12-26 | Allulose-containing composition for promoting excretion of vegetable lipids from the body |
SG11201903370SA SG11201903370SA (en) | 2016-12-26 | 2017-12-26 | Allulose-containing composition for promoting excretion of vegetable lipids from the body |
CN201780080903.7A CN110139563A (zh) | 2016-12-26 | 2017-12-26 | 促进植物脂质排泄出体外的包含阿洛酮糖的组合物 |
CA3041260A CA3041260C (en) | 2016-12-26 | 2017-12-26 | Allulose-containing composition for promoting excretion of vegetable lipids from the body |
CONC2019/0005180A CO2019005180A2 (es) | 2016-12-26 | 2019-05-21 | Composición que contiene alulosa para promover la excreción de lípidos vegetales del cuerpo |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160179488 | 2016-12-26 | ||
KR20160179487 | 2016-12-26 | ||
KR10-2016-0179487 | 2016-12-26 | ||
KR10-2016-0179488 | 2016-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018124704A1 true WO2018124704A1 (ko) | 2018-07-05 |
Family
ID=62711056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/015496 WO2018124704A1 (ko) | 2016-12-26 | 2017-12-26 | 알룰로스를 포함하는, 식물성 유지의 생체 외 배출 촉진용 조성물 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11191285B2 (ko) |
EP (1) | EP3560340A4 (ko) |
KR (1) | KR20180075423A (ko) |
CN (1) | CN110139563A (ko) |
CA (1) | CA3041260C (ko) |
CL (1) | CL2019001510A1 (ko) |
CO (1) | CO2019005180A2 (ko) |
MX (1) | MX2019005996A (ko) |
SG (1) | SG11201903370SA (ko) |
WO (1) | WO2018124704A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7503131B2 (ja) * | 2019-10-29 | 2024-06-19 | サムヤン コーポレイション | アルロースを含有する乳化組成物 |
CN113016714B (zh) * | 2021-03-04 | 2023-08-22 | 湖南中医药大学 | 一种泄泻食滞胃肠证动物模型的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010018528A (ja) * | 2008-07-09 | 2010-01-28 | Matsutani Chem Ind Ltd | 食物繊維と希少糖を含む生体機能改善組成物。 |
JP2016154463A (ja) * | 2015-02-23 | 2016-09-01 | 株式会社希少糖生産技術研究所 | 希少糖を含む植物粉体 |
WO2016182235A1 (ko) * | 2015-05-13 | 2016-11-17 | 주식회사 삼양사 | 혼합당 과립 분말 및 이의 제조방법 |
KR101692033B1 (ko) * | 2015-09-01 | 2017-01-03 | 경북대학교 산학협력단 | D-싸이코스를 유효성분으로 함유하는 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62272938A (ja) * | 1986-05-21 | 1987-11-27 | Miyoshi Oil & Fat Co Ltd | 加糖マ−ガリンの製造方法 |
US5120563A (en) * | 1989-12-21 | 1992-06-09 | The Procter & Gamble Company | Food compositions containing reduced calorie fats and reduced calorie sugars |
US20060247310A1 (en) | 2002-03-04 | 2006-11-02 | Hisami Shinohara | Body temperature elevating agents |
JP5240810B2 (ja) * | 2005-07-20 | 2013-07-17 | 帝國製薬株式会社 | D−プシコースの血中d−フラクトース濃度上昇抑制への使用 |
KR101325061B1 (ko) | 2006-11-10 | 2013-11-05 | 고쿠리츠다이가쿠호우징 카가와다이가쿠 | D-사이코스 함유 감미료 및 그것을 사용하여 얻어진 식품 |
JP2008222656A (ja) | 2007-03-14 | 2008-09-25 | Orient Herb Kk | 肥満改善および予防用組成物ならびに健康食品 |
US20110166224A1 (en) | 2008-08-11 | 2011-07-07 | Kishore Ganesh M | Diacylglycerol rich fats, oils and functional foods |
JP6099870B2 (ja) * | 2012-01-06 | 2017-03-22 | 松谷化学工業株式会社 | スクロースとd−プシコースを含む新規甘味料 |
US20150056360A1 (en) | 2012-04-04 | 2015-02-26 | Nestec S.A. | Creamer composition comprising protein, low molecular weight emulsifiers and hydroxypropyl starch |
KR20160089551A (ko) | 2013-11-22 | 2016-07-27 | 테이트 앤드 라일 인그리디언츠 어메리카즈 엘엘씨 | 알룰로스(프시코스)를 포함하는 식품 및 음료 제품 |
KR101695832B1 (ko) * | 2014-11-07 | 2017-01-12 | 주식회사 삼양사 | 사이코스를 함유하는 제과제빵용 크림 조성물 |
-
2017
- 2017-12-26 EP EP17887817.9A patent/EP3560340A4/en active Pending
- 2017-12-26 MX MX2019005996A patent/MX2019005996A/es unknown
- 2017-12-26 KR KR1020170179550A patent/KR20180075423A/ko not_active Application Discontinuation
- 2017-12-26 US US16/468,345 patent/US11191285B2/en active Active
- 2017-12-26 SG SG11201903370SA patent/SG11201903370SA/en unknown
- 2017-12-26 CN CN201780080903.7A patent/CN110139563A/zh active Pending
- 2017-12-26 CA CA3041260A patent/CA3041260C/en active Active
- 2017-12-26 WO PCT/KR2017/015496 patent/WO2018124704A1/ko active Application Filing
-
2019
- 2019-05-21 CO CONC2019/0005180A patent/CO2019005180A2/es unknown
- 2019-06-04 CL CL2019001510A patent/CL2019001510A1/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010018528A (ja) * | 2008-07-09 | 2010-01-28 | Matsutani Chem Ind Ltd | 食物繊維と希少糖を含む生体機能改善組成物。 |
JP2016154463A (ja) * | 2015-02-23 | 2016-09-01 | 株式会社希少糖生産技術研究所 | 希少糖を含む植物粉体 |
WO2016182235A1 (ko) * | 2015-05-13 | 2016-11-17 | 주식회사 삼양사 | 혼합당 과립 분말 및 이의 제조방법 |
KR101692033B1 (ko) * | 2015-09-01 | 2017-01-03 | 경북대학교 산학협력단 | D-싸이코스를 유효성분으로 함유하는 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
Non-Patent Citations (3)
Title |
---|
HAN, YOUNGJI ET AL.: "D-allulose supplementation normelized the body weight and Fat-pad mass in Diet-induced Obese Mice via the Regulation of Lipid Metabolism unde Isocaloric Fed Condition", MOLECULAR NUTRITION & FOOD RESEARCH, vol. 60, no. 7, 27 February 2016 (2016-02-27), pages 1695 - 1706, XP055600971, DOI: 10.1002/mnfr.201500771 * |
NAGATA, YASUO ET AL.: "d-Psicose, an Epimer of d-Fructose, Favorably Alters Lipid Metabolism in Sprague–Dawley Rats", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 63, no. 12, pages 3168 - 3176, XP055517512, DOI: 10.1021/jf502535p * |
See also references of EP3560340A4 * |
Also Published As
Publication number | Publication date |
---|---|
CA3041260A1 (en) | 2018-07-05 |
CL2019001510A1 (es) | 2019-08-09 |
MX2019005996A (es) | 2019-08-21 |
US11191285B2 (en) | 2021-12-07 |
EP3560340A1 (en) | 2019-10-30 |
KR20180075423A (ko) | 2018-07-04 |
EP3560340A4 (en) | 2020-05-27 |
BR112019008683A2 (pt) | 2019-07-09 |
CA3041260C (en) | 2021-10-26 |
SG11201903370SA (en) | 2019-05-30 |
CO2019005180A2 (es) | 2019-05-31 |
CN110139563A (zh) | 2019-08-16 |
US20200170269A1 (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023110016A (ja) | オレウロペインの生物変換 | |
US11547736B2 (en) | Sauvignon blanc grape seed products for nonalcoholic fatty liver disease | |
WO2018117659A1 (ko) | 청대 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 약학적 조성물 | |
KR20070055528A (ko) | 의학적 증상의 치료에서의 사용을 위한 피토스테롤에스테르(들) 및 1,3-디글리세라이드(들)의 혼합물 | |
WO2009048249A2 (en) | Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same | |
WO2018062914A1 (ko) | 신규한 락토바실러스 사케이 및 이를 포함하는 조성물 | |
US11968990B2 (en) | Creamer comprising vegetable lipids and allulose | |
WO2023038350A1 (ko) | 락토바실러스 혼합균주를 유효성분으로 포함하는, 월경전 증후군 완화용 조성물 | |
US20060247310A1 (en) | Body temperature elevating agents | |
WO2018124704A1 (ko) | 알룰로스를 포함하는, 식물성 유지의 생체 외 배출 촉진용 조성물 | |
KR20040083874A (ko) | 비만개선용 조성물 | |
EP2740473A1 (en) | Composition for the prevention and the treatment of hepatic steatosis and/or cystic fibrosis | |
JPWO2013187391A1 (ja) | セサミン類とγ−オリザノールと米胚芽油とを含有する組成物 | |
EP3701952A1 (en) | Inositol phosphate-containing composition | |
WO2017065328A1 (ko) | 알파-리포익산 및 n-아세틸시스테인을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 | |
KR101139070B1 (ko) | 지방간 개선용 조성물 | |
WO2023043218A1 (ko) | 바실러스 서브틸리스 낫또 배양균체 추출물을 포함하는 기억력 개선용 조성물 | |
WO2014017741A1 (ko) | 프루네틴을 유효성분으로 함유하는 비만 또는 대사성 질환의 예방 또는 치료용 약학적 조성물 | |
EP4260849A1 (en) | Compound for the reduction of white adipose tissue and the treatment of overweight and obesity | |
WO2014178554A1 (ko) | 아르기나아제 억제제를 함유하는 비만 및 지방간 예방 또는 치료용 조성물 | |
WO2011122722A1 (ko) | 콜레스테롤 산화효소를 제조하는 방법, 콜레스테롤 산화효소를 이용하여 식물스테롤 발효물을 생산하는 방법, 이 식물스테롤 발효물을 이용한 체지방 개선용 기능성 조성물, 식품 및 건강기능성식품 | |
WO2019088541A2 (ko) | 단삼 추출물을 함유하는 내장지방형 비만 예방, 개선 또는 치료 조성물 | |
WO2019004733A2 (ko) | 쌍별귀뚜라미 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물 | |
JP2013180953A (ja) | Srebp1抑制剤 | |
WO2013172528A1 (ko) | 아스테루빈의 신규 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17887817 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3041260 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019008683 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112019008683 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190429 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017887817 Country of ref document: EP |